Clinical Trials at UCHealth University of Colorado Hospital
As of June 2026, 57 paid clinical trials are recruiting at UCHealth University of Colorado Hospital, located at 12605 E 16TH AVE, AURORA, CO 80045-2545, phone (720) 848-0000 in Aurora, Colorado. Active studies at this site cover conditions such as Breast Cancer, Obesity and Heart Failure. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
57 clinical trials at UCHealth University of Colorado Hospital
·Clear filters·↓ Download CSVEvaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
E-Mindfulness Approaches for Living After Breast Cancer
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Onyx™ Liquid Embolic IDE Clinical Study
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part B
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
About research studies in Aurora
Aurora has approximately 1,099 recruiting research studies across a wide range of therapeutic areas. Colorado hosts the University of Colorado Anschutz Medical Campus, National Jewish Health, and Children's Hospital Colorado, with strong programs in pulmonology, oncology, and cardiovascular research.
Common conditions studied in Aurora
- Breast Cancer (27 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Obesity (18 active studies). Obesity trials evaluate GLP-1 and GIP receptor agonists, novel metabolic drugs, and combined lifestyle interventions for sustainable weight loss.
- Heart Failure (13 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Type 1 Diabetes (13 active studies). Type 1 diabetes research investigates immune-modulating therapies, stem cell–derived islet replacement, and closed-loop insulin delivery systems.
- Colorectal Cancer (12 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Melanoma (12 active studies). Melanoma trials test immune checkpoint inhibitors, adoptive cell therapies, and BRAF/MEK targeted combinations in both early and metastatic disease.
Leading research sponsors in Aurora
- University of Colorado, Denver
- National Cancer Institute (NCI)
- VA Office of Research and Development
- Children's Oncology Group
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Colorado are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Colorado trials are additionally subject to the Colorado Privacy Act (CPA), which adds consumer data-protection requirements to federal baseline standards.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Aurora. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Aurora
Hipa.ai aggregates every recruiting study in Aurora from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Aurora?
There are approximately 1,099 recruiting clinical trials in Aurora, Colorado listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Aurora pay participants?
Most recruiting trials in Aurora compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Aurora?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Aurora?
The most common conditions under active study in Aurora include Breast Cancer (27), Obesity (18), Heart Failure (13), Type 1 Diabetes (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Aurora?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Aurora on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Aurora?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Aurora?
Recruiting research sites in Aurora include Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, University of Colorado, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Aurora right now?
The largest active categories in Aurora are Cancer & tumors (315), Diabetes & metabolic (85), Neurology & pain (73). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of UCHealth University of Colorado Hospital?
UCHealth University of Colorado Hospital is located at 12605 E 16TH AVE, AURORA, CO 80045-2545. Use the Google Maps link in the intro above to get directions.
How do I contact UCHealth University of Colorado Hospital?
You can reach UCHealth University of Colorado Hospital by phone at (720) 848-0000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.